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Background
C-type natriuretic peptide (CNP) is a paracrine factor
that stimulates long bone growth, axonal path finding
and inhibits meiosis in the oocyte [1]. The biologic sig-
naling receptor for CNP is guanylyl cyclase (GC)-B, also
known at NPRB or NPR2 [2].
GC-B is a homo-oligomer, possibly a dimer, containing a
glycosylated extracellular ligand-binding domain, a single
membrane-spanning region, and intracellular kinase
homology domain (KHD), dimerization domain and
C-terminal GC catalytic domain. Phosphorylation of the
region leading into and at the beginning of the kinase
homology domain is required for CNP activation of GC-B
and dephosphorylation inactivates the enzyme [3].
Homozygous inactivating mutations in GC-B result in
Acromesomelic Dysplasia, Type Maroteaux (AMDM)
dwarfism [4-6], and heterozygous inactivating mutations
in GC-B cause non-pathological reductions in stature
[7]. Conversely, genetic mutations that increase GC-B
activity result in skeletal overgrowth [8-10].
More than fifteen inactivating missense mutations in
GC-B have been identified in humans. These mutations
are randomly distributed from the N-terminus (P32) to
the C-terminus (G959A) of the enzyme, consistent with
two potential mechanisms. The first involves multiple
processes like disruption of CNP or GTP binding to the
extracellular or catalytic domains, respectively. The sec-
ond more general mechanism involves conformational
changes in secondary, tertiary or quaternary structure
that preclude catalytic domain formation or activation.
Previous investigators reported that 11 out of 12 [1], 2
out of 3 [2] or 1 out of 2 [3] missense mutations inhibited
the transport of GC-B to the cell surface due to defective
cellular trafficking and retention in the ER as indicated
by reduced immunofluorescence imaging. Thus, the cur-
rent hypothesis is that AMDM mutations inactivate GC-
B by disrupting intracellular trafficking. Here, we report
that four intracellular GC-B mutants known to cause
AMDM dwarfism bind CNP on the cell surface but have
dramatically reduced catalytic activity.
Results
AMDM mutants are incompletely processed- Post-or
co-translational processing of the four intracellular
AMDM causing mutants (L658F, Y708C, R776W and
G959A) was compared against WT-GC-B and GC-B-7A,
a mutant containing alanine substitutions for all known
phosphorylation sites [3], in reduced SDS gels contain-
ing immunoprecipitated receptors isolated from transi-
ently transfected 293T cells. Coomassie staining (Fig. 1,
upper panel) of WT-GC-B revealed a slower migrating,
diffuse species (top band) that is maximally glycosylated
and phosphorylated and a faster migrating species (bot-
tom band) that is incompletely glycosylated and is not
phosphorylated [3-14]. The upper band was also present
in samples from GC-B-7A indicating that changes in
phosphorylation does not account for the difference in
migration of the two bands. In contrast, all four AMDM
mutants had severe reductions in the slower migrating,
fully glycosylated and phosphorylated species, but had nor-
mal amounts of the faster migrating, incompletely glycosy-
lated species. ProQ Diamond staining, a dye that binds
GC-B in phosphate-dependent manner [5], of the same
gel indicated that only the slower migrating species of the
WT receptor was phosphorylated (Fig. 1, lower panel).
The AMDM GC-B Mutants Are On the Cell Surface
and Bind CNP- 125I-CNP binding assays were performed
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on live 293T cells transfected with the individual AMDM
mutants, WT-GC-B as a positive control, and GFP as a
negative control (Fig. 2, upper panel). Low radiation levels
in GFP transfected cells and in GC-B expressing cells
incubated with excess non-radioactive CNP (nonspecific
binding), confirmed that the binding was specific for GC-
B. All four mutants specifically bound 125I-CNP, consis-
tent with GC-B being on the cell surface. Total 125I-CNP
binding to each mutant was variable and less than that
observed for the WT receptor, which is expected since the
mutants lack the upper completely processed species only
seen in WT-GC-B (Fig. 1, upper panel). Competition bind-
ing assays indicated that the affinity of each mutant for
CNP was similar to that of the WT-GC-B (Fig. 2, lower
panel). These data indicate that all four mutants are on
the cell surface and that glycosylation of GC-B is neither
required to bind CNP nor required for GC-B to adopt a
conformation capable of binding CNP.
AMDM mutants have dramatically reduced GC activity-
The ability of the GC-B mutants to form active catalytic
domains that can be stimulated by CNP or non-ionic
detergent and manganese was tested in membranes from
transfected 293 cells (Fig. 3). GC activity was measured
under basal (Mg2+GTP and ATP), CNP-stimulated
(Mg2+GTP, ATP, CNP) and artificial (Mn2+GTP and Tri-
ton X-100) conditions. The latter activates the enzyme
independently of natriuretic peptide or phosphorylation
and is an excellent indicator of total catalytic domain for-
mation [3]. No significant differences were observed under
basal condition but GC activities of the mutant enzymes
measured under CNP- and detergent conditions was less
than 20% of the activity observed for WT-GC-B. Since the
AMDM mutations inhibit activity in the presence of deter-
gent and CNP, it suggests that catalytic domain formation
is inhibited as opposed to inhibiting CNP-dependent acti-
vation of a preformed catalytic domain.
Conclusion
We conclude that glycosylation of GC-B is required for
active catalytic domain formation and that the majority
Figure 1 AMDM mutants are not processed to the fully
glycosylated and phosphorylated form of GC-B. WT and the
indicated missense versions of GC-B were isolated from transiently
transfected 293T cells by sequential immunoprecipitatin/SDS-PAGE
purification. The resulting gel was incubated with ProQ Diamond
dye to determine GC-B phosphate levels (lower panel). The same
gel was then washing and stained with Coomassie to determine
the amount of GC-B protein present (upper panel). MW in Kilo-
Daltons is shown for protein standards on left. Abbreviations are:
GFP, green fluroscent protein; 7A, GC-B containing alanine
substitutions for all seven known phosphorylation sites.
Figure 2 The AMDM mutants are on the cell surface and bind
CNP like WT-GC-B. 293 cells were transiently transfected with
plasmids containing green fluorescent protein (GFP), WT-GC-B or
the indicated mutants. Cells were incubated for 1 hr at 4°C with 50
pM 125I-CNP in the presence or absence of 1 μM (upper panel) or
increasing concentrations (lower panel) of non-radioactive CNP. The
cells were rinsed with binding medium to remove non-specific 125I-
CNP, removed from the plate with NaOH, and subjected to gamma
counting to determine the amount of specifically bound 125I-CNP
associated with the cells. The vertical arrows in the bars and
symbols represent the SEM where n = 3.
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of GC-B mutations that reduce stature inactivate the
enzyme by decreasing receptor glycosylation not by inhi-
biting trafficking to the plasma membrane.
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Figure 3 The AMDM mutants have markedly reduced guanylyl
cyclase activity. 293 cells were transiently transfected with
plasmids containing green fluorescent protein (GFP), WT-GC-B or
the indicated mutants of GC-B. Crude membranes were prepared
from the transfected cells and assayed for guanylyl cyclase activity
under basal, CNP-stimulated or Triton X-100 and manganese-
stimulated conditions. The vertical arrows in the bars and symbols
represent the SEM where n = 3.
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